Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in Jul...
April 23 2018 - 7:00AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage
specialty neuropsychiatric pharmaceutical company dedicated to
developing and commercializing innovative pharmaceutically-produced
transdermal cannabinoid treatments for rare and near-rare
neurological and psychiatric disorders with high unmet medical
needs, today announced an oral presentation to be given at the16th
NFXF (National Fragile X Foundation) International Fragile X
Conference. The event is being held at the Hiatt Regency in
Cincinnati, OH, July 11-15, 2018.
The oral presentation will describe data from the
FAB-C (Treatment of Fragile X Syndrome
Anxiety and Behavioral Challenges
with CBD) study that highlight the short- and
long-term positive impact of ZYN002 on children and adolescents
with Fragile X syndrome (FXS).
Accepted for Oral Presentation
Abstract 347: |
|
“Transdermal Cannabidiol (CBD) Gel for the Treatment of
Fragile X Syndrome" |
Session
name: |
|
Industry
Updates |
Session
date: |
|
Thursday
July 12, 2018 |
Session
presentation time: |
|
5:30PM –
6:30PM EDT |
Room: |
|
Regency
Ballroom |
“We are excited to present these important data to the FXS
community; Zynerba is committed to supporting the needs of
patients, their families and health care practitioners, and to
developing this novel therapy to treat the behavioral symptoms
associated with Fragile X syndrome as expeditiously as possible,”
said Dr. Liza Squires, Zynerba’s Chief Medical Officer. “We are
currently preparing for the initiation of a pivotal trial in FXS
which we anticipate will initiate mid-year 2018.”
About Zynerba Pharmaceuticals, Inc. Zynerba
Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage specialty
pharmaceutical company dedicated to developing and commercializing
innovative pharmaceutically-produced transdermal cannabinoid
treatments for rare or near-rare neuropsychiatric diseases with
high unmet medical needs. We are dedicated to improving the lives
of people with severe health conditions by developing cannabinoid
medicines designed to meet the rigorous efficacy and safety
standards established by global regulatory agencies. Through the
discovery and development of these potentially life-changing
medicines, Zynerba seeks to improve the lives of patients battling
severe, chronic health conditions including Fragile X syndrome,
refractory epilepsies, Tourette Syndrome, and other
neuropsychiatric disorders. Learn more at www.zynerba.com and
follow the Company on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company’s current
expectations. For example, there can be no guarantee that the
Company will obtain approval for ZYN002 from the U.S. Food and Drug
Administration (FDA) or foreign regulatory authorities; even if
ZYN002 are approved, the Company may not be able to obtain the
label claims that it is seeking from the FDA. In addition, the
Company’s cash and cash equivalents may not be sufficient to
support its operating plan for as long as anticipated.
Management’s expectations and, therefore, any forward-looking
statements in this press release could also be affected by risks
and uncertainties relating to a number of other factors, including
the following: the success, cost and timing of the Company’s
product development activities, studies and clinical trials; the
success of competing products that are or become available; the
Company’s ability to commercialize its product candidates; the size
and growth potential of the markets for the Company’s product
candidates, and the Company’s ability to service those markets; the
Company’s ability to develop sales and marketing capabilities,
whether alone or with potential future collaborators; the rate and
degree of market acceptance of the Company’s product candidates;
and the Company’s expectations regarding its ability to obtain and
adequately maintain sufficient intellectual property protection for
its product candidates. This list is not exhaustive and these and
other risks are described in the Company’s periodic reports,
including the annual report on Form 10-K, quarterly reports on Form
10-Q and current reports on Form 8-K, filed with or furnished to
the Securities and Exchange Commission and available
at www.sec.gov. Any forward-looking statements that the
Company makes in this press release speak only as of the date of
this press release. The Company assumes no obligation to update
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Zynerba ContactWill Roberts, VP Investor
Relations and Corporate
Communications484.581.7489robertsw@zynerba.com
Media contactTheresa Dolge Tonic Life
CommunicationsOffice: 215-928-2748Theresa.Dolge@toniclc.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2024 to May 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From May 2023 to May 2024